Stevens Capital Management LP Invests $12.84 Million in Stryker Co. (SYK)

Stevens Capital Management LP acquired a new position in shares of Stryker Co. (NYSE:SYK) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 81,938 shares of the medical technology company’s stock, valued at approximately $12,844,000. Stryker accounts for about 0.7% of Stevens Capital Management LP’s holdings, making the stock its 23rd largest holding.

Several other large investors have also modified their holdings of the stock. Northwest Wealth Management LLC grew its position in Stryker by 103.6% in the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock valued at $26,000 after acquiring an additional 86 shares in the last quarter. Horan Securities Inc. acquired a new position in Stryker in the 4th quarter valued at about $30,000. Moody National Bank Trust Division acquired a new position in Stryker in the 4th quarter valued at about $32,000. Westside Investment Management Inc. grew its position in Stryker by 38.7% in the 4th quarter. Westside Investment Management Inc. now owns 233 shares of the medical technology company’s stock valued at $37,000 after acquiring an additional 65 shares in the last quarter. Finally, Exane Derivatives acquired a new position in Stryker in the 4th quarter valued at about $39,000. 74.99% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have weighed in on the company. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a research report on Monday, February 4th. SunTrust Banks lifted their target price on Stryker to $205.00 and gave the company a “positive” rating in a research report on Monday, February 4th. Credit Suisse Group raised Stryker to an “outperform” rating in a research report on Thursday, January 31st. Canaccord Genuity lifted their price objective on Stryker from $185.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, January 30th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Stryker in a research note on Friday, January 18th. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $185.37.

In other news, insider Timothy J. Scannell sold 9,332 shares of the stock in a transaction dated Tuesday, December 18th. The stock was sold at an average price of $161.60, for a total value of $1,508,051.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael Damon Hutchinson sold 10,109 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $180.14, for a total value of $1,821,035.26. The disclosure for this sale can be found here. Insiders sold 43,259 shares of company stock worth $7,515,747 in the last three months. 7.30% of the stock is owned by corporate insiders.

SYK stock opened at $186.00 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.02 and a quick ratio of 1.41. Stryker Co. has a fifty-two week low of $144.75 and a fifty-two week high of $185.81. The company has a market cap of $68.34 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 2.25 and a beta of 0.86.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.15 by $0.03. The business had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. As a group, sell-side analysts anticipate that Stryker Co. will post 8.12 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 1.12%. The ex-dividend date of this dividend is Thursday, March 28th. Stryker’s dividend payout ratio (DPR) is 28.45%.

ILLEGAL ACTIVITY WARNING: “Stevens Capital Management LP Invests $12.84 Million in Stryker Co. (SYK)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2019/02/13/stevens-capital-management-lp-invests-12-84-million-in-stryker-co-syk.html.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: Understanding the different types of bonds

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit